AU2016338639A1 - Therapeutic targeting of casein kinase 1delta in breast cancer - Google Patents

Therapeutic targeting of casein kinase 1delta in breast cancer Download PDF

Info

Publication number
AU2016338639A1
AU2016338639A1 AU2016338639A AU2016338639A AU2016338639A1 AU 2016338639 A1 AU2016338639 A1 AU 2016338639A1 AU 2016338639 A AU2016338639 A AU 2016338639A AU 2016338639 A AU2016338639 A AU 2016338639A AU 2016338639 A1 AU2016338639 A1 AU 2016338639A1
Authority
AU
Australia
Prior art keywords
cancer
breast cancer
ck1s
catenin
mda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016338639A
Other languages
English (en)
Inventor
John L. Cleveland
Derek R. Duckett
Laura H. Rosenberg
William R. Roush
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of AU2016338639A1 publication Critical patent/AU2016338639A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016338639A 2015-10-13 2016-10-05 Therapeutic targeting of casein kinase 1delta in breast cancer Abandoned AU2016338639A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562240689P 2015-10-13 2015-10-13
US62/240,689 2015-10-13
PCT/US2016/055436 WO2017066055A1 (en) 2015-10-13 2016-10-05 THERAPEUTIC TARGETING OF CASEIN KINASE 1δ IN BREAST CANCER

Publications (1)

Publication Number Publication Date
AU2016338639A1 true AU2016338639A1 (en) 2018-05-10

Family

ID=58517824

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016338639A Abandoned AU2016338639A1 (en) 2015-10-13 2016-10-05 Therapeutic targeting of casein kinase 1delta in breast cancer

Country Status (8)

Country Link
US (2) US10603322B2 (cg-RX-API-DMAC10.html)
EP (1) EP3362452A4 (cg-RX-API-DMAC10.html)
JP (1) JP2018538241A (cg-RX-API-DMAC10.html)
CN (1) CN108431006A (cg-RX-API-DMAC10.html)
AU (1) AU2016338639A1 (cg-RX-API-DMAC10.html)
CA (1) CA3001903A1 (cg-RX-API-DMAC10.html)
HK (1) HK1259409A1 (cg-RX-API-DMAC10.html)
WO (1) WO2017066055A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018112342A1 (en) * 2016-12-16 2018-06-21 The Johns Hopkins University Chemical inhibitors against kinases to block telomere elongation in cancer
WO2019145386A1 (en) 2018-01-26 2019-08-01 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating csnk1d expression
US11666578B2 (en) 2018-05-08 2023-06-06 The University Of Florida Research Foundation, Inc. Small molecule inhibitors of CDK12/CDK13
CN113271962A (zh) * 2018-08-22 2021-08-17 默克专利有限公司 利用靶向TGF-β抑制的三阴性乳腺癌的治疗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493464B2 (en) * 2012-02-29 2016-11-15 The Scripps Research Institute Wee1 degradation inhibitors
SG11201505446WA (en) * 2013-01-16 2015-08-28 Signal Pharm Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
US20180311252A1 (en) 2018-11-01
EP3362452A1 (en) 2018-08-22
US20200163972A1 (en) 2020-05-28
CN108431006A (zh) 2018-08-21
CA3001903A1 (en) 2017-04-20
JP2018538241A (ja) 2018-12-27
US10603322B2 (en) 2020-03-31
HK1259409A1 (zh) 2019-11-29
WO2017066055A1 (en) 2017-04-20
EP3362452A4 (en) 2019-06-12

Similar Documents

Publication Publication Date Title
Giraud et al. Verteporfin targeting YAP1/TAZ‐TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells
Wang et al. EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A
Rosenberg et al. Therapeutic targeting of casein kinase 1δ in breast cancer
Wang et al. Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of β-catenin stabilization in cancer stem cells
Yang et al. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK–ERK pathway in pancreatic cancer
Hornsveld et al. FOXO transcription factors both suppress and support breast cancer progression
Hu et al. G9a and histone deacetylases are crucial for Snail2‐mediated E‐cadherin repression and metastasis in hepatocellular carcinoma
Zhang et al. CBX8 exhibits oncogenic activity via AKT/β-catenin activation in hepatocellular carcinoma
Po et al. Hedgehog-GLI signalling promotes chemoresistance through the regulation of ABC transporters in colorectal cancer cells
Tang et al. MicroRNA‐324‐5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling
Konsavage et al. Wnt/β-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal carcinoma cells
Li et al. Lamin B1 is a novel therapeutic target of betulinic acid in pancreatic cancer
Tao et al. miR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer
Guerrant et al. YAP mediates tumorigenesis in neurofibromatosis type 2 by promoting cell survival and proliferation through a COX-2–EGFR signaling axis
Liu et al. Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2
Jung et al. Zinc finger protein 746 promotes colorectal cancer progression via c-Myc stability mediated by glycogen synthase kinase 3β and F-box and WD repeat domain-containing 7
Liu et al. The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy
US20200163972A1 (en) Therapeutic Targeting of Casein Kinase 1 Delta in Breast Cancer
Liu et al. METTL3 inhibitor STM2457 impairs tumor progression and enhances sensitivity to anlotinib in OSCC
Wang et al. CD24 mediates gastric carcinogenesis and promotes gastric cancer progression via STAT3 activation
Hagen et al. RABL6A Promotes G1–S Phase Progression and Pancreatic Neuroendocrine Tumor Cell Proliferation in an Rb1-Dependent Manner
Wojnarowicz et al. Anti-tumor effects of an ID antagonist with no observed acquired resistance
Ho et al. Inhibition of the H3K9 methyltransferase G9A attenuates oncogenicity and activates the hypoxia signaling pathway
Dai et al. Let-7 sensitizes KRAS mutant tumor cells to chemotherapy
Zhu et al. LINC00365 promotes colorectal cancer cell progression through the Wnt/β‐catenin signaling pathway

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application